Author

S. Nagelli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

J. Westermarck· 2 shared A. Cvrljevic· 1 shared A. Laine· 1 shared C. Farrington· 1 shared C. Lucas· 1 shared D. Connolly· 1 shared E. Loyttyniemi· 1 shared E. Makela· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Westermarck

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis

A. Laine, S. Nagelli, C. Farrington, U. Butt, A. Cvrljevic, J. Vainonen, T. Gronroos, P. Gautam, S. Khan, H. Sihto, X. Qiao, D. Connolly, P. Kronqvist, J. Maurer, K. Wennerberg, , J. Westermarck

This study identifies CIP2A as a subtype-specific driver of DNA damage-induced basal-like breast cancer, showing its role in checkpoint signaling and therapeutic vulnerability.

bioRxiv · Aug 27, 2020Cancer Biology

Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias

E. Makela, K. Pavic, T. Varila, U. Salmenniemi, E. Loyttyniemi, S. Nagelli, V.-M. Kahari, R. E. Clark, V. K. Bachanaboyina, C. Lucas, M. Itala-Remes, J. Westermarck

The paper discovers a novel CIP2A splicing variant, NOCIVA, which is overexpressed in myeloid leukemias and correlates with poor clinical outcomes.

bioRxiv · Aug 24, 2020Cancer Biology